Eleven Biotherap (EBIO) Misses Q3 EPS by 22c

Eleven Biotherap (NASDAQ: EBIO) reported Q3 EPS of ($0.66), $0.22 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $539 thousand versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on Eleven Biotherap (EBIO) click here.

You May Also Be Interested In

• BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
• Mount Logan's Ability Insurance launches MYGA annuity products
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance